Identifying mutations in SARS-CoV-2, especially functional variants, and their distributions in the population, is crucial to successfully inoculate individuals against COVID-19, as well as to identify and treat new cases. Therefore, Doğa Eskier, Dr. Gökhan Karakülah and Dr. Yavuz Oktay from IBG sought to identify the distribution and variances of three major SARS-CoV-2 variants (B.1.1.7,
Dr. Ezgi Karaca and the group members of the Karaca Lab at IBG, recently questioned whether in-silico prediction tools could foresee the impact of recently proposed ACE2 designer mutations. We know that ACE2 serves as the host receptor for the SARS-Cov2 virus. Spike proteins that are present on the surface of the virus membrane bind
Multiple sequence alignment (MSA), whether peptide or nucleotide, can be stored in multiple formats, most commonly Clustal’s .aln format or the FASTA format. While these files are plain text files, and can be opened and edited in any text editor, performing many of the tasks common to MSA analysis in such editors is unintuitive and
We estimated the full impact of the mutatome of 17 SARS-CoV-2 genomes isolated in Turkey, obtained from GISAID, on the tertiary structures of the coronavirus proteins. To this end, we employed multiple sequence alignment to identify changes in the amino acid sequences of 10 SARS-CoV-2 proteins, except surface glycoprotein, which we investigated in our previous
We have compared the genomes of 17 SARS-CoV-2 isolates in Turkey that have been sequenced to the reference genome sequence using multiple sequence alignment methods in order to identify any major structural variations. Our results are as follows: * 12 isolates have a 265-nucleotide long deletion on the 5’ end of the genome. No other
Mutations in the genome of a virus can complicate attempts to combat viral diseases, whether by causing a higher number of false negatives in diagnosis methods, such as by PCR, or attenuating or eliminating the effects of anti-viral medication or vaccination by disrupting the pharmacokinetic interactions of viral proteins with administered substances or preventing antibodies